Turn the tide against the liver's silent killer – NASH
Introducing a non-invasive blood test for advanced liver fibrosis due to NASH
As many as 4 to 6 million people are projected to have advanced fibrosis due to NASH1
By 2030, NASH (non-alcoholic steatohepatitis) is predicted to be the #1 leading indication for liver transplant.1,2 Our Enhanced Liver Fibrosis (ELF™) Test is the first blood test granted De Novo marketing authorization by the FDA for prognosis in advanced fibrosis due to NASH.
Meet a few Siemens Healthineers colleagues working to help turn the tide against the liver's silent killer – NASH
Want to know more about our innovations? Join us for the AACC 2021 Virtual Experience.